Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cambridge Antibody Technology and Molecular Partners have signed a cross-license agreement, under which both companies will have substantial freedom to conduct research using some of each others' intellectual property, as well as the right to develop therapeutic, prophylactic and diagnostic products.
Subscribe to our email newsletter
Cambridge Antibody Technology (CAT) obtains access to Molecular Partners’ proprietary designed repeat proteins (DRPs) technology and Molecular Partners gains rights to intellectual property in ribosome display, controlled by CAT, in the field of novel protein products.
Under the terms of the agreement, Molecular Partners obtains the right to use CAT’s intellectual property in ribosome display to develop an unlimited number of DRP products for biotechnological tests and reagents, diagnostic tests and reagents, and therapeutics in all fields. In addition, Molecular Partners receives the right to sublicense the ribosome display with the DRP technology to third parties.
CAT obtains the right under the Molecular Partners’ patents to develop and commercialize products using Molecular Partners’ DRP technology, including the right to sublicense these products to collaboration partners.